### Notice of Special Interest (NOSI): Telehealth Research in Cancer Care NOT-CA-24-033 Frequently Asked Questions (FAQ)

Pre-application Webinar held May 15, 2024 Slides and a videorecording of the Webinar are available at:

https://healthcaredelivery.cancer.gov/media/webinars.html

https://cancercontrol.cancer.gov/brp/events/telehealth-in-cancer-care

### **Application Instructions and Eligibility**

Q1: Are we only permitted to apply for one of the PARs listed on the NOSI solicitation?

A1: Yes. If you would like to apply to the NOSI, you may only submit your application to the PARs listed on the NOSI, or their reissuances, if applicable.

Q2: What is the funding opportunity announcement number for R21s?

A2: PAR-22-165 and PAR-21-341

Q3: Can we apply for this NOSI if we have a K award?

A3: Please check the restrictions of your specific K award to determine your eligibility to apply for any R01 or R21 grant while funded by a K award.

Q4: Will resubmissions be considered after the NOSI expires?

A4: All of the PARs listed on the NOSI accept resubmissions and will do so even after the NOSI expires. You would simply refrain from citing the expired NOSI in the SF424 for your resubmission.

Q5: Can my application have a foreign component?

A5: Foreign components are discouraged due to the unique health care and telehealth context in the U.S.

#### Scope

Q6: Our planned provider-patient focused telehealth intervention fits within the scope of interventions you identified (targets primary and secondary behavior change). However, the intervention is implemented by health educators (usually MPHs, RDs) not professionals traditionally considered as providers (i.e., MDs, Dos, NPs). Are we eligible to apply?

### Q7: What do you mean by "stand alone" mHealth studies (described as unresponsive)?

A7: Any mHealth intervention that is a technology-mediated intervention (e.g., text, app) that is not connected to health care delivery or oncology care.

### Q8: What modes of interactions are included in telehealth?

A8: A broad range of technology-mediated interactions are used in telehealth. These may include real-time video calls, telephone calls, and communications through a patient portal.

### Q9: Are implementation or effectiveness aims more appropriate?

A9: Either is acceptable and appropriate, but it would depend on your research questions and the current state of science for the intervention.

## Q10: Is the NOSI interested in quality assessment and evaluation of care delivery in telehealth?

A10: Yes. A rigorous study design(s) for the quality assessment and evaluation of care delivery in telehealth is essential.

# Q11: Would an application to conduct a tobacco treatment program or other health behavior intervention via telehealth be eligible?

A11: Yes.

Q12: If I have an existing telehealth intervention, could I apply for funds to evaluate the effects of new policies on telehealth on that intervention's recruitment or conduct?

A12: Yes.

# Q13: Is this NOSI interested in understanding recruitment limitations or differences based on different state telehealth policies?

A13: Yes.

### General

### Q14: Where will applications be reviewed?

A14: Applications to NOSIs are not reviewed by Special Emphasis Panels. They will be reviewed by standing Center for Scientific Review (CSR) study sections and triaged based on topic.